Portfolio
Portfolio

Glycart

Research and development of engineered antibody-based products.

GLYCART biotechnology AG was active in the research and development of engineered antibody-based products with higher efficacy for the treatment of unmet clinical needs such as cancer.

GLYCART biotechnology AG was acquired by Roche in 2005 for CHF 230 million.

  • Industry Biotech
  • History M&A